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Abstract
Background: Recently, there has been a surge of interest in developing compounds selectively targeting mitochondria for
the treatment of neoplasms. The critical role of mitochondria in cellular metabolism and respiration supports this
therapeutic rationale. Dysfunction in the processes of energy production and metabolism contributes to attenuation of
response to pro-apoptotic stimuli and increased ROS production both of which are implicated in the initiation and
progression of most human cancers.
Methodology/Principal Findings: A high-throughput MTT-based screen of over 10,000 drug-like small molecules for anti-
proliferative activity identified the phosphonium salts TP187, 197 and 421 as having IC50 concentrations in the
submicromolar range. TP treatment induced cell cycle arrest independent of p53 status, as determined by analysis of DNA
content in propidium iodide stained cells. In a mouse model of human breast cancer, TP-treated mice showed significantly
decreased tumor growth compared to vehicle or paclitaxel treated mice. No toxicities or organ damage were observed
following TP treatment. Immunohistochemical staining of tissue sections from TP187-treated tumors demonstrated a
decrease in cellular proliferation and increased caspase-3 cleavage. The fluorescent properties of analog TP421 were
exploited to assess subcellular uptake of TP compounds, demonstrating mitochondrial localization. Following mitochondrial
uptake cells exhibited decreased oxygen consumption and concomittant increase in mitochondrial superoxide production.
Proteomics analysis of results from a 600 target antibody microarray demonstrated that TP compounds significantly
affected signaling pathways relevant to growth and proliferation.
Conclusions/Significance: Through our continued interest in designing compounds targeting cancer-cell metabolism, the
Warburg effect, and mitochondria we recently discovered a series of novel, small-molecule compounds containing a
triphenylphosphine moiety that show remarkable activity in a panel of cancer cell lines as well as in a mouse model of
human breast cancer. The mechanism of action includes mitochondrial localization causing decreased oxygen consumption,
increased superoxide production and attenuated growth factor signaling.
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Introduction
Phosphonium salts have broad utility, with applications in
chemistry, biology and pharmacology. Triphenylphosphine can
easily react with alcohols, alkyl halides, and carboxylic acids giving
rise to a large variety of chemical entities, which supports their
wide applicability. Initially, phosphonium salts were used in
preparation of phosphorus ylides, an essential component in the
Wittig method of alkene synthesis.[1] As a reagent for biological
research, the lipophilic, cationic properties of tetraphenylpho-
sphonium were first utilized to demonstrate the existence of
electrochemical potential across the mitochondrial membrane.[2]
Charged molecules are generally unable to traverse cell mem-
branes without the aid of transporter proteins due to the large
activation energies associated with removal of associated water
molecules. The distribution of charge across the large lipophilic
surface of the phosphonium ion significantly lowers this energy
requirement facilitating passage across lipid membranes.[3] Thus
phosphonium salts accumulate in energized mitochondria due to
their highly negative membrane potential. Based on this
observation, the triphenylphosphonium ion has been used as a
targeting moiety for delivery of agents such as spin traps,
fluorescent dyes, and antioxidants to isolated mitochondria, as
well as the mitochondria of intact cells and whole organisms. As
pharmacological agents, certain phosphonium salts have demon-
strated anti-microbial activity against gram negative and positive
bacteria and the parasite T. cruzi., antiglycemic properties in
animal models and anti-proliferative activity in cell- and animal-
based systems.[4,5,6,7] As anti-cancer agents, phosphonium salts
show great promise for the diagnosis and treatment of neoplasms.
For reasons that are not fully understood, many solid tumors have
a more negative mitochondrial membrane potential compared to
their normal counterparts.[8] This trait can be exploited to allow
selective delivery to tumor cells, while sparing normal cells for both
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proliferative activity was reported in 1978 following routine
screens of synthetic intermediates.[9] In these screens isoindoly-
lalkyl phosphonium salts showed potent anti-leukemic activity.
More recently, some phosphonium salts have been reported to
show anti-proliferative activity in several cancer cell lines and a
xenograft model of ovarian cancer based on their ability to disrupt
mitochondrial ultrastructure and alter cellular lipid con-
tent.[7,10,11,12] Studies of phosphonium salts as contrast agents
for diagnostic imaging [13,14] have elucidated two key points
concerning the selectivity of this class of compounds: 1) these
agents are capable of preferentially accumulating within tumor
cells, 2) that phosphonium cation itself does not impart
cytotoxicity.
Herein we describe a series of novel compounds containing a
triphenylphosphine moiety that show remarkable activity in a
panel of cancer cell lines. Two of these compounds were tested in a
mouse xenograft model and showed significant in vivo efficacy
with no apparent toxicity. Further molecular characterization of
these compounds in cell-based models suggest a mechanism of
action that includes mitochondrial localization, decreased oxygen
consumption, increased superoxide production and attenuated
growth factor signaling.
Results
TP compounds are cytotoxic in a panel of human cancer
cell lines
We have in place a highly diverse library of small molecules
comprised of approximately 40,000 chemical entities. For the
present study, a subset of 10,000 compounds predicted in silico to
have favorable drug-like properties was selected for in vitro studies.
Initial screening to identify active compounds was performed using
a high-throughput 96-well format MTT-based cytotoxicity assay
in a panel of cancer cell lines of varied origin. This screening
method identified lead compounds, TP187 and TP197, having
cytotoxicity values in the low micromolar range. IC50 values
obtained in MTT assay are listed in Table 1. These results were
further confirmed in colony formation assay using HCT116 p53
+/+ cells treated with increasing concentrations of TP187, 197
and the close analogue TP421 (Fig. 1A). All three TP compounds
exhibited IC50 values in the low micromolar range across most cell
lines tested in MTT (Table 1) as well as in HCT116 p53 +/+
colony assays (Fig. 1B) and were, therefore, selected for further
analysis in cell- and animal-based models.
TP compounds arrest cell cycle progression in human
cancer cell lines
Flow cytometry was performed on ethanol-fixed propidium
iodide stained tumor cell lines treated with 1 mM TP187 for 24–
72 h to investigate the effect of TP compounds on cell cycle
progression and DNA content. TP187 arrested cell cycle progres-
sion in all cell lines, starting at 24 h treatment. (Fig. 1C–E) MDA-
MB-435, a p53 mutant cell line, arrested in the S-Phase of the cell
cycle in response to treatment with TP187. (Fig. 1C) HCT116 p53
+/+ (Fig. 1D) and HCT116 p532/2 (Fig. 1E), p53competent and
deficient cell lines, respectively, both exhibited cell cycle arrest in
the G2/M phase of the cell cycle when treated with TP187. These
effects on cell cycle progression were sustained through the 72 h
timepoint. Based on these results, the mechanism of action was
concluded to be independent of p53 status.
TP compounds inhibit tumor growth in vivo
Next, we tested the TP analogues 187, 197 and 449 in a nude
mouse xenograft model to determine the in vivo efficacy of these
compounds. Treatment of MDA-MB-435 xenografts with TP
compounds as single agents significantly inhibited tumor growth in
both TP187 and TP197 treatment groups compared to vehicle
controls. (Fig. 2A) Starting at day 13, significant differences in
tumor volume were noted between TP187 and 197 treated mice
compared to controls. (TP187; p,0.05, TP197; p,0.05) The
suppressive effects of TP187 and 197 were maintained throughout
the course of treatment (at day 33 TP187; p=0.003 and TP197;
p=0.04). Upon conclusion of treatment at day 33, the average
tumor volume of vehicle treated tumors increased by 1149%,
whereas the average tumor volume in TP187 and 197 treated
groups increased less than 373 and 573%, respectively. TP449
treatment also suppressed tumor growth but statistical analysis
showed p values to be greater than that considered significant.
(TP449; p.0.05).
TP treated mice exhibit no sign of drug related toxicity
Mice were monitored daily by visual inspection and weighed
three times per week to detect symptoms of drug related toxicity.
TP-treated mice showed no outward signs of drug related toxicity
such as malaise, weakness or lethargy throughout the entire 33-day
treatment course. TP197 was initially administered at similar
dosing but due to slight decrease in weight (,10% of body weight)
within the first week, treatment was modified to dosing at 10 mg/
kg, three times weekly. Soon after the dose adjustment TP197
treated mice resumed gaining weight, and by the end of the
experiment weights were similar to that of the controls. Despite the
reduction in number of doses of drug administered, TP197
retained its efficacy in suppression of tumor growth.
In addition to daily health checks, organ samples were
collected at the time of sacrifice (day 33) to evaluate for potential
drug related toxicities at the cellular level. Tissue samples derived
from brain, heart, lung, liver, kidney, pancreas and spleen were
harvested from mice in all treatment groups. These samples were
subsequently fixed in 10% neutral buffered formalin, paraffin
embedded and stained with H&E for histological analysis.
Careful examination of these tissue sections demonstrated no
Table 1. Cytotoxicity of TP compounds in various cancer cell
lines.
Cell line IC50
TP187 TP197
MDA MB 435 0.8 60.1 0.860.1
MDA MB 361 12.060.1 0.860.1
MDA MB 231 2.260.1 1.060.1
PC3 1.760.1 0.760.1
DU145 1160.1 1.260.1
BT474 .2060.1 0.660.1
T47D 1.060.1 0.460.1
CAMA1 1060.1 1.460.1
MCF7 0.860.1 1.360.1
NCI ADR RES .2060.1 2.060.1
HCT116 p53 +/+ 0.460.1 0.460.1
HCT116 p53 2/2 1.360.1 1.360.1
HOP92 6.060.1 1.560.1
doi:10.1371/journal.pone.0013131.t001
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from TP-treated compared to control mice. Representative
micrographs comparing tissue sections of liver, kidney, brain
and spleen taken from control and TP187 treated mice are
presented in Fig. 2B.
TP187 decreases the number of proliferating cells and
induces caspase-3 cleavage in tumor xenografts
The suppression of tumor growth in response to TP187
treatment prompted us to examine tumor sections for histological
markers that could validate our in vivo results. Immunohistochem-
ical staining (IHC) was performed on formalin-fixed, paraffin-
embedded tumor sections collected from vehicle- and TP187-
treated treated mice to evaluate the effect of treatment on cell
proliferation and apoptosis. Tumor sections were processed as
described in the methods section and probed using antibodies
against Ki-67 and cleaved caspase-3.
Ki-67 is a cell-cycle related protein. Its presence solely in
actively cycling cells makes it an ideal marker to identify the
fraction of proliferating cells within a tissue sample. Ki-67
expression is increased in rapidly dividing cell populations and
the degree and intensity of Ki-67 staining can be correlated with
prognosis and response to treatment in many solid tumors.[15,16]
Ki67 expression was nearly absent in all TP187 treated tumor
sections. A representative micrograph of the decrease in Ki-67
staining is shown in Fig. 2C, upper panel. Evaluation of Ki-67
expression using a semi-quantitative method of tissue scoring
shows treatment of MDA-MB-435 xenografts with TP187 resulted
in a significant decrease (p,0.001) in Ki-67 staining in comparison
to vehicle treated xenografts (Fig. 2D). This result correlates well
with the observed suppression of tumor growth in vivo.
Next we sought to determine whether our compound could
induce cell death in vivo. Caspases are cysteine-aspartate specific
proteases that, upon cleavage by upstream proteases, function in
apoptotic cell death pathways. Caspase 3 is a downstream
executioner caspase common to both the intrinsic and extrinsic
pathways of apoptosis. Cleavage of caspase 3 is a late and
irreversible event in the process of apoptosis and therefore serves
as a marker for both major apoptotic pathways leading to cell
death.[17] Compared to vehicle-treated, TP187-treated tumor
sections showed increased cytoplasmic staining with anti-cleaved
caspase 3 antibody (Fig. 2C, middle panel).
Figure 1. TP compounds decrease cell proliferation and induce cell cycle arrest independent of p53 status. (A) Structures of lead
compounds TP187, 197 and 421. (B) Colony formation assay was performed using HCT116 p53 +/+ cells treated continuously for 7 days with TP
compounds at the noted concentrations. Cells were treated in triplicate and results are representative of three separate experiments. DNA content
was analyzed in propidium iodide stained MDA-MB-435 (C), HCT116 p53 +/+ (D) and HCT116 p53 2/2 (E) cell lines treated for up to 72 h with 1 mM
TP compounds. Light grey bars represent the G0/G1 fraction, dark grey bars represent cell in S phase and black bars correspond to cells in the G2/M
phase of the cell cycle.
doi:10.1371/journal.pone.0013131.g001
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models with no systemic toxicities. (A) Graph shows average tumor volumes amongst the treatment groups over the course of the experiment.
Vehicle control (green square) and TP187 (red triangle) were administered five times weekly, TP197 (open purple triangle) was administered three
times weekly. Paclitaxel (closed blue circle) was administered every other day over a period of 15 days. Tumor volumes were measured three times
weekly, error bars represent SEM. (B) Representative micrographs of H&E stained organ tissue collected from vehicle and TP187 treated mice. (C).
Immunohistochemical staining was performed on tumor sections collected from vehicle and TP187 treated mice. Ki67 staining (upper) was
significantly decreased in TP187 treated mice compared to control. Caspase 3 cleavage (middle) was increased in TP187 treated tumor sections versus
vehicle treated tumors. An H&E staining of tumor sections is shown in the middle panel. Micrographs are representative of three separate
experiments. (D). Graph shows the average Q-score values calculated for 10 random high power fields from the three separate mice within each
treatment group. Q-score is a semi-quantitative method of tissue scoring that considers both percent and intensity of positively stained cells in a
Mitochondria-Targeted Drugs
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Ki-67 staining and an increase in caspase 3 cleavage in response to
treatment with TP compounds. Taken together, these results
suggest a mechanism, acting on effectors of cell proliferation and
death pathways that together, are capable of suppressing tumor
growth in vivo.
TP compounds localize to the mitochondria
The favorable results obtained in vivo prompted us to further
characterize the molecular mechanisms of TP mediated tumor
suppression and identify potential targets of TP action. To this
end, we chose to first investigate the subcellular localization of TP
compounds in an effort to narrow the range of possible targets.
The triphenylphosphonium moiety common to the TP com-
pounds imparts a delocalized charge and lipophilic character that
favors mitochondrial accumulation.[3,18] Therefore, we tested
whether our compounds could accumulate preferentially in the
mitochondria by exploiting the fluorescent properties of the analog
TP421. We performed fluorescence spectroscopy to determine the
optimal excitation and emission wavelengths using a steady state
spectrofluorimeter. TP421 has an optimal excitation wavelength of
396 nm. Excitation peaks of nearly similar intensity were observed
at 450 nm and 573 nm (Fig. 3A) with 450 nm having slightly
higher peak intensity.
Based on the excitation/emission spectra we were able to
measure the uptake of TP421 using fluorescence-based assays.
MDA-MB-435 cells were treated with 5 mM TP421 and analyzed
by flow cytometry using a 355 nm UV-laser as the excitation
source and optical filters capable of capturing emission in the
450 nm range. MDA-MB-435 cells treated with 5 mM TP421
displayed a sharp increase in fluorescence intensity (Fig. 3B)
compared to cells treated with a comparable volume of DMSO.
The intensity of fluorescence increased immediately upon addition
of TP421, leveling off to a steady state with 15 minutes (data not
shown) suggesting that TP uptake is rapid and likely due to the
lipophilic nature and delocalized charge of the triphenylpho-
sphonium moiety.
Next we examined the subcellular localization of TP421 using
fluorescent microscopy. MDA-MB-435 cells were incubated with
MitoSOX Red, following treatment with TP421. MitoSOX Red is
a mitochondriotropic probe that exhibits fluorescence at excitation
and emission wavelengths of 510 and 588 nm. Fluorescence
microscopy of co-treated MDA-MB-435 cells revealed similar
staining patterns using filters appropriate for each probe
suggesting that TP421 does indeed localize to the mitochondria
(Fig. 3C).
TP compounds increase mitochondrial superoxide
production
Energy production through oxidative phosphorylation is the
primary function of the mitochondria. Inhibition of components of
the oxidative phosphorylation machinery is known to result in the
increased production of superoxide ion. [24,25] The mitochon-
drial localization of TP compounds therefore, led us to investigate
superoxide production as a possible mechanism of action for our
compounds.
To examine the effect of TP treatment on mitochondrial
superoxide production, we treated MDA-MB-435 cells with 5 mM
of TP197 for varying lengths of time. At the end of treatment, cells
were incubated with 5 mM of MitoSOX red and change in
fluorescence intensity corresponding to production of superoxide
was measured by flow cytometry. In order to rule out the
possibility that our observations could be the result of non-specific
ROS production in response to xenobiotic treatment, we also
included MDA-MB-435 cells treated with paclitaxel.
Using this fluorogenic mitochondrial superoxide indicator, we
found that TP197 treatment caused increased production of
mitochondrial superoxide. MDA-MB-435 cells were treated with
5 mM TP197 and collected at various time points ranging from 10
minutes up to 24 hours. Overlays of histograms showing mean
fluorescence intensity are presented in Fig. 3D. The surge in
superoxide production was observed at time points as early as 10
minutes post treatment, increased to maximal intensity by 3 h post
treatment and remained increased for 24 h following treatment
with TP197 (Fig. 3E). Similar results were obtained measuring
superoxide production in TP187 and TP421 treated MDA-MB-
435 cells at 0.5 and 1, 6 and 24 h time points (data not shown). In
contrast, paclitaxel treatment had no effect on the production of
mitochondrial superoxide, as fluorescence intensity was un-
changed compared to the vehicle control.
TP compounds decrease the cellular rate of oxygen
consumption
Based on the observed preferential accumulation of TP
compounds in the mitochondria and subsequent superoxide
production, we chose to examine what effect this might have on
mitochondrial respiration. To this end, we measured the rates of
oxygen consumption (OCR) and extracellular acidification
(ECAR) in real-time using the XF 24 Extracellular Flux Analyzer.
MDA-MB-435 cells were treated with either TP187, TP197,
TP421 or DMEM control followed by sequential addition of
oligomycin, an ATP synthase inhibitor, FCCP, an uncoupling
agent and the complex I inhibitor, rotenone. OCR and ECAR
were measured at short intervals over a period of 7 hours.
TP compounds decrease cellular oxygen consumption in a dose
dependent manner (data not shown). Treatment of MDA-MB-435
cells with TP187, TP197 and TP421 resulted in a steady decrease
in the rate of oxygen consumption (Fig. 4A). The TP-induced
decrease in OCR was sustained throughout the entire 7 h time
course and was unaffected by treatment with the various metabolic
inhibitors. Upon addition of oligomycin, vehicle treated cells
exhibited a decrease in the rate of oxygen consumption, similar to
that seen with TP treatment. Meanwhile, OCR in the TP treated
cells was unaffected by addition of oligomycin. Uncoupling of
mitochondrial respiration from ATP synthesis by FCCP caused a
large spike in the rate of oxygen consumption in vehicle treated
cells, but TP treated cells did not respond at all to FCCP
treatment. Addition of rotenone to vehicle treated cell completely
abrogated the spike in OCR induced by FCCP, lowering OCR to
levels similar to those obtained with TP treatment alone.
Rotenone did not decrease the already low OCR levels in TP
treated MDA-MB-435 cells. The rapid and sustained decrease in
OCR suggests that TP compounds act to decrease the efficiency of
oxidative phosphorylation.
The decrease in OCR in response to TP187, TP197 and
TP421 was accompanied by an increase in ECAR. (Fig. 4B)
Treatment with TP187 steadily increased ECAR reaching a peak
rate approximately 1 hour post treatment, after this point, ECAR
steadily declined yet remained above control values at all
given tissue samples. Q-values were significantly decreased in TP187 treated tumor sections (p,0.001). Micrographs and Q-scores are the results of
three separate experiments.
doi:10.1371/journal.pone.0013131.g002
Mitochondria-Targeted Drugs
PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13131Figure 3. The fluorescent properties of TP421 were exploited to determine cellular uptake and localization. Upper panel, optimal
excitation and emission spectra are 396 and 450 nm, respectively for TP421, as determined using steady state fluorescence spectroscopy. The graph
shows the emission spectra of TP421. Middle panel, TP421 uptake can be monitored by flow cytometry. Histogram shows fluorescence intensity
measured at excitation 355 nm and emission 450 nm prior to, and following treatment with TP421. Microscopy of cytospin of TP421 treated cells
show subcellular localization suggestive of mitochondrial accumulation. Mitochondrial superoxide production is an early and sustained event in TP
action. MDA-MB-435 cells were treated with 5 mM TP197 and superoxide production was measured at various timepoints using MitoSOX Red, a
fluorogenic indicator of mitochondrial superoxide production. (D) Histogram overlays show the effect of TP treatment at early timepoints. Superoxide
production increased as early as 10 minutes post-treatment (dark blue line) and maintained similar levels at 20 (purple line), 30 (orange line), 60
(brown line), and 120 (green line) minutes post-treatment. Treatment with 500 nM paclitaxel (olive line) did not increase superoxide levels above
those seen in vehicle (solid red) treated cells. (E) Superoxide production is increased through later timepoints. TP-induced superoxide production was
measured 3 h (dark blue line), 6 h (purple line ), 18 h (orange line), and 24 h (brown line) after TP197 treatment. Compared to vehicle (solid red) and
paclitaxel (olive line) controls, TP197 caused a marked increase in superoxide production.
doi:10.1371/journal.pone.0013131.g003
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increase in ECAR, a momentary dip in ECAR at 15 minutes post
treatment and an immediate recovery leading to a peak rate at
approximately 75 minutes post treatment followed by a steady
decline in ECAR lasting the duration of treatment. TP421 caused
a sharp increase of ECAR that reached peak rate approximately
25 minutes post treatment with a sustained downward trend.
Control cells treated with oligomycin exhibited an increase in the
rate of ECAR, whereas TP421 treated cells exhibited an initial
decrease that quickly returned to levels seen at the TP421
treatment baseline. Oligomycin had no effect on the rate of
ECAR in TP treated cells. The uncoupler, FCCP increased
ECAR in control cells. TP treatment caused a momentary
decrease in ECAR that was soon regained to restore levels to
those seen with TP treatment alone. Rotenone caused a slight
decrease in ECAR in control cells but had little affect on TP
treated cells.
Proteomics analysis of TP mechanism of action using
antibody microarray
In an effort to further understand the mechanism of action of
our compounds, we sought to examine their global effect on
signaling proteins in MDA-MB-435 cells. To that end we
employed the use of the Kinex
TM KAM-1.1 Antibody Microarray.
These antibody arrays are capable of detecting changes in either
the phosphorylation status or the total abundance of nearly 600
well-characterized proteins representing a fraction of the total
cellular proteome. Specifically, our samples were screened against
378 pan-specific (measuring total protein abundance) and 273
phospho-site-specific antibodies.
MDA-MB-435 cells were treated with either vehicle control or
TP421 for 24 hours, and then collected, lysed, and sent for
analysis. We selected compound TP421, because initial screening
revealed it to be the most potent of the analogues in the MDA-
MB-435 cell line, which was used for the proteomics experiment.
All of the information obtained to date indicated that the
analogues act with the same mechanism of action, though modest
cell type-specific sensitivity was observed. Therefore, the results of
the proteomics screen obtained using TP421 were extended to
TP187 and TP197.
Of the panel of nearly 400 proteins interrogated by the chip
bound antibodies, 103 proteins showed significant changes in
either abundance or phosphorylation state following TP421
treatment. Those proteins identify potential signaling pathways
sensitive to TP421 and likely also to its analogues, TP187 and
TP197.
TP421 and analogues affect proteins involved in key
cellular functions
The proteins whose expression or post-transcriptional modi-
fication is significantly altered in response to TP treatment along
with the fold change relative to control treated cells are listed in
Tables 2, 3 and 4. Interestingly, many of the proteins sig-
nificantly modulated are key effectors in processes or signal
transduction pathways regulating cell proliferation, adhesion,
intracellular survival signaling, and metabolism and gene
transcription. Treatment with TP421 for 24 h significantly
altered the abundance or phosphorylation of proteins involved
in cell cycle entry and/or progression: CDK1, CDK7, CDC25B,
p21CDK1L, cyclin D1, cyclin A1, cyclin E1, PAK3, RB (T821)
and p73; focal adhesions and cytoskeletal organization: ILK1,
paxillin 1, ROCK1, caldesmon, FAK (S722), Pyk2 (S579), cofilin
(total and S3), vinculin (Y821), LIMK 1/2 (Y507/T508, Y504/
T505); receptor tyrosine kinases: VEGFR2 (Y1054), IR (Y999),
c-Kit (Y936), PDGFRa (Y742); intracellular signaling kinases
and effectors: PKA Ca/b, CAMK2g, CASK/Lin2, RIP2/
RICK, SIRPa1, CAMK2a (T286), PAK 1/2/3 (S144/S141/
S154), PKCb 1/2 (T500), PKCw (T655), PKCc (T674), PKCd
(Y313), RSK1/2 (S363/S369), and eNOS (T495); cell survival
and apoptosis: PKB (S473) and JNK (T183 + Y185); cell
proliferation and differentiation: MEK3b, MEK1 (S297, T385),
and MEK2 (T394); regulators of transcription: STAT3, STAT6,
STAT2 (Y690), and c-Jun (S73); energy sensing, glucose
metabolism and transcriptional acitivation: pyruvate kinase 2,
adenylate kinase 2, PCK2, mTOR (S2448), eIF4E (total &
S209), eIF2a (S51). Furthermore, TP treatment increased the
expression of several key intracellular phosphatases including:
PP1, PP2a, PP2Cd PP4/A’2, PP5C, PTP1C and PAC1 and
decreased expression of molecular chaperones: HspBP1, Hsp60
and Grp78.
Figure 4. Oxygen consumption is decreased in TP treated MDA-MB-435 cells. OCR and ECAR were measured using the XF 24 Extracellular
Flux Analyzer. Addition of TP compounds resulted in a decrease in OCR with a simultaneous increase in ECAR. The observed decrease in OCR was not
affected by addition of inhibitors of ATP synthase, uncoupling agents or complex I inhibition. [Port A: TP compound (5 mM), Port B: Oligomycin
(0.005 mg/mL), Port C: FCCP (1 mM) Port D: Rotenone (1 mM).
doi:10.1371/journal.pone.0013131.g004
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Ingenuity Pathway Analysis
The data identifying affected proteins was further analyzed
using Ingenuity software package (Ingenuity Systems Inc.) to
illustrate protein-protein interaction networks, which are generat-
ed by connecting the proteins showing significant changes to
TP421 treatment and relating them in biological context. In this
way, the experimental data can be scrutinized for relationships,
mechanisms, functions, and pathways of relevance regarding the
mechanism of action of our compound.
Another global functional analysis feature displays key biological
processes and pathways to visualize potentially interesting changes
in tumor biology in response to TP421 treatment. In addition, the
software was used to statistically rank the various pathways in
order of significance (Fig. 5).
Of over 70 pathways ranked by the software, the top ranked is
the Hepatocyte Growth Factor signaling pathway (Fig. 6). This
pathway represents a very likely target of TP421 treatment and
possibly its close analogues TP187 and TP197 as well. Several key
kinases and signaling molecules in this pathway are either
significantly up-regulated (seen in red) or down-regulated (seen
in green) following addition of our compound to cells. This
pathway is particularly intriguing because it signals to several key
downstream effectors that mediate cell survival, death, adhesion
and motility, and progression through the cell cycle, all of which
are vital to cancer cell proliferation. For some of the proteins
affected in this pathway, the total abundance was changed, while
for others, specific phosphorylation sites were either increasingly
phosphorylated or dephosphorylated following TP421 treatment.
For the latter proteins, the effect of phosphorylation on their
function is described in Table 5.
Discovery of novel, active TP analogues
Based on the activity of TP187, TP197 and TP421, an
additional 700 structural analogues containing the triphenylpho-
sphonium moiety were designed and screened for cytotoxicity in
HCT116 p53 +/+, a colon carcinoma cell line. Compounds
displaying more than 50% cytotoxicity at 10 mM were selected for
Table 2. Results of TP421 proteomics screen for proteins whose total abundances were decreased in response to TP421
treatment.
Protein Name Full Protein Name Fold Change
HspBP1 Hsp70 binding protein 1 23.44
CK1e Casein protein-serine kinase 1 epsilon 23.02
CDK1 (CDC2) Cyclin-dependent protein-serine kinase 1 22.62
Csk C-terminus of Src tyrosine kinase 22.60
DAPK1 Death-associated protein kinase 1 22.52
Cyclin D1 Cyclin D1 (PRAD1) 22.24
CAS Cellular apoptosis susceptibility protein (CSE1L) 22.14
PKCa Protein-serine kinase C alpha 22.10
Cdc25B Cell division cycle 25B phosphatase 22.04
Hsp60 Heat shock 60 kDa protein 1 (chaperonin, CPN60) 21.94
SIRPa1 Signal regulatory protein substrate of PTP1D phosphatase (SHPS1) 21.90
ALS2CR7 (PFTAIRE2) Amyotrophic lateral sclerosis 2 chromosomal region candidate gene protein-serine kinase 7 21.83
Grp78 Glucose regulated protein 78 21.79
FasL Tumor necrosis factor ligand, member 6 21.74
PKA Ca/b cAMP-dependent protein-serine kinase catalytic subunit alpha/beta 21.72
CAMK2g Calcium/calmodulin-dependent protein-serine kinase 2 gamma 21.59
ANKRD3 Ankyrin repeat domain protein-serine kinase 3 (RIPK4, DIK) 21.56
CASK/Lin2 Calcium/calmodulin-dependent protein-serine kinase (Lin2 homolog) 21.54
HO1 Heme oxygenase 1 21.52
p21 CDKI1 Cyclin-dependent kinase inhibitor 1 (MDA6) 21.50
ILK1 Integrin-linked protein-serine kinase 1 21.49
PCK2 Phosphoenolpyruvate carboxykinase 21.46
CDK1 (CDC2) Cyclin-dependent protein-serine kinase 1 21.45
Cyclin A Cyclin A1 21.42
Cdc34 Cell division cycle 34 (ubiquitin-conjugating ligase) 21.39
AK2 Adenylate kinase 2 21.39
p73 Tumor suppressor protein p73 21.38
LATS1 Large tumor suppressor 1 protein-serine kinase (WARTS) 21.37
CDC2L5 (CHED) Cell division cycle 2-like protein-serine kinase 5 21.35
PAK3 p21-activated serine kinase 3 (beta) 21.34
doi:10.1371/journal.pone.0013131.t002
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MCF-7, PC3, HCT116 p53+/+ and HCT 116 p53-/-. The
compounds having IC50 values #5 mM in MTT assay are
displayed in Fig. 7 and results are reported in Table 6. The
cytotoxicity of these compounds was subsequently tested by colony
formation assay. With the exception of a few compounds, a good
correlation was observed between the results obtained in the two
assays. (Table 6) These outcomes indicate that the presence of a
TP moiety alone is not sufficient for cytotoxicity. Although a
number of close analogues of TP187, TP197 and TP421 were
screened, we were unable to identify a coherent structure activity
relationship between analogues due to similar levels of activity
between analogues.
Discussion
The tumor microenvironment is characterized by alterations in
oxygen and nutrient content based, in part, on the inadequacies of
tumor vasculature. The tortuous, disorganized tumor vascular bed
produces hypoxic, nutrient poor regions within growing tumors.
Survival in these sub-optimal conditions requires tumor cells
invoke adaptive strategies to circumvent nutrient deprivation and
hypoxia. Alterations in energy metabolic pathways and the
adaptive responses to hypoxia and nutrient deprivation are
emerging as hallmarks of cellular transformation. [19] Midway
into the 20
th century, Warburg postulated that even with adequate
oxygenation, cancer cells rely on glycolytic metabolism as an
Table 3. Results of TP421 proteomics screen for proteins whose total abundances were increased in response to TP421 treatment.
Protein Name Full Protein Name Fold Change
PAC1 Dual specificity MAP kinase protein phosphatase 1.27
STAT3 Signal transducer and activator of transcription 3 (acute phase response factor) 1.28
SPHK2 Sphingosine kinase 2 1.31
MEK3b (MAP2K3) MAPK/ERK protein-serine kinase 3 beta isoform (MKK3 beta) 1.32
Caveolin 2 Caveolin 2 1.32
CDK7 Cyclin-dependent protein-serine kinase 7 1.35
PP1/Cg Protein-serine phosphatase 1 - catalytic subunit - gamma isoform 1.35
PKG1 Protein-serine kinase G1 (cGMP-dependent protein kinase) 1.38
Paxillin Paxillin 1 1.39
IKKg/NEMO I-kappa-B kinase gamma/NF-kappa-B essential modulator(NEMO) 1.39
RIP2/RICK Receptor-interacting serine/threonine-protein kinase 2 (RIPK2) 1.39
PKCq Protein-serine kinase C theta 1.43
Tyro3 Tyrosine-protein kinase receptor TYRO3 1.44
DRAK2 DAP kinase-related apoptosis-inducing protein-serine kinase 2 (STK17B) 1.45
Cofilin Cofilin 1 1.47
NT5E Ecto-59-nucleotidase (CD73 antigen) 1.47
eIF4E Eukaryotic translation initiation factor 4 (mRNA cap binding protein) 1.48
PP5C Protein-serine phosphatase 5 - catalytic subunit (PPT) 1.50
Cyclin E Cyclin E1 1.50
Nip1 Bcl2/adenovirus E1B 19kD-interacting protein 1 1.51
ICK Intestinal cell protein-serine kinase (MAK-related kinase (MRK)) 1.52
PP4/A’2 Protein-serine phosphatase 4 - regulatory subunit (PPX/A’2) 1.52
PARP1 Poly [ADP-ribose] polymerase 1 (ADPRT) 1.54
Haspin Haploid germ cell-specific nuclear protein-serine kinase 1.55
PKM2 Pyruvate kinase, isozymes M1/M2 1.60
TBK1 Tank-binding protein 1 1.62
IKKa Inhibitor of NF-kappa-B protein-serine kinase alpha (CHUK) 1.66
hHR23B UV excison repair protein RAD23 homolog B 1.74
Fyn Fyn proto-oncogene-encoded protein-tyrosine kinase 1.74
STAT6 Signal transducer and activator of transcription 6 1.75
PCTK1 (PCTAIRE1) PCTAIRE-1 protein-serine kinase 2.02
PP2Cd Protein-serine phosphatase 2C - catalytic subunit - delta isoform 2.05
PTP1C Protein-tyrosine phosphatase 1C (SHP1, SHPTP1) 2.12
IR Insulin receptor beta chain 2.18
Aurora A (AIK) Aurora Kinase A (serine/threonine protein kinase 6) 2.18
ROKb (ROCK1) Rho-associated protein kinase 1 2.21
PP2A/Ca Protein-serine phosphatase 2A - catalytic subunit alpha isoform 2.59
doi:10.1371/journal.pone.0013131.t003
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mitochondrial respiratory chain.[20] More recent knowledge
demonstrates results to the contrary in some tumor types
suggesting the Warburg effect may not apply to all cancers. Poor
tumor cell perfusion limits glucose supply considerably making
glycolysis energetically unsustainable. Measured oxygen levels in
hypoxic tumor tissues are higher than that at which respiratory
dysfunction is thought to occur, precluding hypoxia as a cause of
mitochondrial dysfunction.[21] Through examining the contribu-
tions of each metabolic pathway to cell proliferation it has been
observed that oxidative phosphorylation supplies a large portion of
the ATP produced in many tumor types, particularly in the
absence of glucose. Furthermore, cell-based studies demonstrate
an increase in cancer cells’ oxidative phosphorylation capacity and
oxygen affinity upon prolonged culture in glucose free media and
the requirement of functional mitochondria to activate survival
mechanisms such as the unfolded protein response (UPR) pathway
under glucose starved conditions.[22,23] All of which are not
observed in non-transformed cell lines. Tumors exhibit additional
metabolic changes, including de novo lipid and nucleotide
Table 4. Results of TP421 proteomics screen for proteins whose phosphorylation levels were changed in response to TP421
treatment.
Protein Name Phosphorylation Site Full Protein Name Fold Change
CaMK2a T286 Calcium/calmodulin-dependent protein-serine kinase 2 alpha 23.02
Lck Y191 Lymphocyte-specific protein-tyrosine kinase 22.93
JNK T183+Y185 Jun N-terminus protein-serine kinases (stress-activated protein kinase (SAPK)) 1/2/3 22.90
Jun S73 Jun proto-oncogene-encoded AP1 transcription factor 22.68
MEK1 (MAP2K1) S297 MAPK/ERK protein-serine kinase 1 (MKK1) 22.61
PKA Ca/b T197 cAMP-dependent protein-serine kinase catalytic subunit alpha/beta 22.11
VEGFR2 (KDR) Y1054 Vascular endothelial growth factor receptor-tyrosine kinase 2 (Flk1) 21.96
Histone H3 T11 Histone H3.3 21.96
RSK1/2 S363/S369 Ribosomal S6 protein-serine kinase 1/2 21.93
IR (INSR) Y999 Insulin receptor 21.92
Histone H3 S28 Histone H3.3 21.85
PAK1/2/3 S144/S141/S154 p21-activated protein-serine kinase 1/2/3 21.84
PKCb1/2 T500 Protein-serine kinase C beta 1/2 21.83
Jun S73 Jun proto-oncogene-encoded AP1 transcription factor 21.83
PKBa (Akt1) S473 Protein-serine kinase B alpha 21.81
Vinculin Y821 Vinculin 21.77
Kit Y936 Kit/Steel factor receptor-tyrosine kinase 21.70
MEK2 (MAP2K2) T394 MAPK/ERK protein-serine kinase 2 (MKK2) (human) 21.65
PKCh T655 Protein-serine kinase C eta 21.61
eIF2a S51 Eukaryotic translation initiation factor 2 alpha 21.56
MEK1 (MAP2K1) T385 MAPK/ERK protein-serine kinase 1 (MKK1) 21.55
LIMK1/2 Y507+T508/Y504+T505 LIM domain kinase 1/2 21.52
eNos T495 Nitric-oxide synthase, endothelial 21.49
FAK S722 Focal adhesion protein-tyrosine kinase 21.44
Caldesmon S789 Caldesmon 21.42
MEK1 (MAP2K1) S297 MAPK/ERK protein-serine kinase 1 (MKK1) 21.35
mTOR (FRAP) S2448 Mammalian target of rapamycin (FRAP) 1.25
STAT2 Y690 Signal transducer and activator of transcription 2 1.27
eIF4E S209 Eukaryotic translation initiation factor 4 (mRNA cap binding protein) 1.27
Tau S578 Microtubule-associated protein tau 1.31
PKCg T674 Protein-serine kinase C gamma 1.35
PDGFRa Y742 Platelet-derived growth factor receptor kinase alpha 1.52
Cofilin 1 S3 Cofilin 1 1.58
Pyk2 Y579 Protein-tyrosine kinase 2 1.58
Tau S738 Microtubule-associated protein tau 1.75
PKCd Y313 Protein-serine kinase C delta 2.05
Tau S530 Microtubule-associated protein tau 2.26
Rb T821 Retinoblastoma-associated protein 1 3.22
doi:10.1371/journal.pone.0013131.t004
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A subset of total ranked pathways is shown here.
doi:10.1371/journal.pone.0013131.g005
Figure 6. Top ranked HGF signaling pathway. Molecules in green are down-regulated in our microarray results while those in red are up-
regulated. Proteins whose phosphorylation level was affected by TP421 treatment are denoted by *.
doi:10.1371/journal.pone.0013131.g006
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ations allow for growth under adverse conditions, generation of
substrates for glycosylation reactions, and supply of precursors for
biosynthetic reactions [24,25]. Often, TCA cycle intermediates are
co-opted as precursors for the biosynthetic reactions. Citrate
derived from the TCA cycle is utilized as a precursor for fatty acid
Table 5. Phosphorylation sites of proteins belonging to the Hepatocyte Growth Factor signaling pathway affected by TP421
treatment.
Protein Name Phosphorylation Site Effect on Protein Function*
Fold Change in Response to
Treatment
Akt S473 Activating phosphorylation 21.81
FAK S722 Unknown 21.44
JNK T183 + Y185 Activating phosphorylation 22.90
c-JUN S73 Activating phosphorylation 22.68
MEK1 S297+T385 Induce interaction with ERK1/2 and regulate enzymatic activity 22.61
MEK2 T394 Unknown 21.65
PAK1/PAK2/PAK3 S144/S141/S154 May affect kinase activity 21.84
PKC beta 1/2 T500 Unknown 21.83
PKC delta Y313 Promotes apoptotic effect of PKC delta 2.05
PKC gamma T674 Unknown 1.35
PKC eta T655 May play a role in mediating PKC eta signaling events 21.61
*Source: www.phosphosite.org.
doi:10.1371/journal.pone.0013131.t005
Figure 7. Structural analogues of TP 187, TP 197 and TP 421.
doi:10.1371/journal.pone.0013131.g007
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amino acids required for protein and nucleotide synthesis. To
compensate, cancer cells have higher uptake of glutamine for
replenishing TCA cycle intermediates through glutaminolysis.[26]
Taken together, these evidence suggest that drugs targeting the
mitochondrial respiratory capacity should have a profound effect
on tumor growth while sparing normal cells.
Herein we have identified a series novel triphenylphosphine
based compounds exhibiting potent anti-tumor activity. Our
preliminary screening of TP analogues 187, 197 and 421
demonstrated cytotoxicity in a panel of cancer cell lines of varied
origin and cytogenetic attributes, inhibition of colony formation at
submicromolar concentrations and cell cycle arrest independent of
p53 competence. TP analogues 187 and 197 significantly
suppressed the growth and proliferation of MDA-MB-435 tumors
in a mouse xenograft at clinically achievable dosing. Daily health
monitoring and post-mortem histology revealed no detectable
systemic toxicities or drug related tissue injury. Collectively, these
results demonstrate the potential clinical utility of TP compounds
in the treatment of a wide range of cancer types.
Using the fluorescent analog TP421 we were able to confirm
rapid uptake and mitochondrial localization as is expected for
compounds containing the triphenylphosphine moiety. Early
events in TP induced apoptosis included a decrease in the rate
of oxygen consumption, a concomitant increase in superoxide
production and transient increase in glycolytic capacity. TP
treatment of MDA-MB-435 cells caused an immediate and
sustained decrease in oxygen consumption that was unaffected
Table 6. IC50 of structural analogues of TP 187, TP 197 and TP 421 in a panel of cancer cell lines.
S.No. Compound
Molecular
weight (G) IC50 (mM)
MCF-7 MDA-MB435 PC3 HCT116 p53+/+ HCT116 p53-/-
MTT CFA MTT CFA MTT CFA MTT CFA MTT CFA
1 TP 783 477.34 2.8 2.2 1.6 3.8 2.8 3 2 1.4 2.7 1.8
2 TP 831 495.33 2.8 3.5 3.4 4.1 3 1.1 2.8 1.6 2.7 3.8
3 TP 738 492.36 3.2 2.8 3.8 2.2 2.8 1 2.8 2.8 3.2 3.1
4 TP 791 500.63 4 3 4 2.9 3.8 3 3.5 5 5.8 .10
5 TP 734 528.69 4.2 2.4 4.2 10 3.4 4 5 .10 6 .10
6 TP 728 503.01 3.8 1.1 3.4 2.8 3.7 3.1 3.1 2.9 3.1 2.3
7 TP 794 565.08 3 2.4 2.8 3.5 3 3.1 2.8 3.2 2.6 3
8 TP 752 489.98 5 3.2 8.4 .1 0 544655
9 TP 749 565.08 2.6 .10 2.5 .10 2.2 8.5 3.1 .10 3.1 4
10 TP 759 592.64 3.1 0.8 3.8 4 3 2.9 1.8 3 3.1 2.8
11 TP 790 390.46 0.8 3.2 0.78 4.1 3 3.2 2.8 6 3.2 3
12 TP 744 432.54 0.65 0.3 2.5 2 3 3.4 1.5 3.1 1.8 3.9
13 TP 726 494.61 0.5 0.15 0.6 2.1 0.5 3.2 0.4 2.4 0.58 2.8
14 TP 824 510.67 0.3 0.38 0.6 1.5 0.42 0.22 0.3 0.6 0.4 0.48
15 TP 760 492.59 0.5 0.28 0.98 0.18 3 0.31 0.31 0.6 0.42 0.78
16 TP 737 501.00 0.5 0.31 1 1.1 0.58 0.6 1.8 3.2 2.5 3
17 TP 736 535.44 5 2.8 5 4 4 3.4 3.8 3 4 3
18 TP 822 572.70 1 2.8 1.5 6 2.8 2 3.5 2.8 2.9 3.2
19 TP 772 420.46 0.65 0.7 5 3.2 1.6 0.6 0.9 2.8 3.1 3
20 TP 731 483.42 0.45 0.2 0.5 0.35 0.4 0.28 0.25 0.28 0.35 0.32
21 TP 768 435.48 0.45 1.1 0.5 3.2 3 0.8 0.99 3.1 2.1 3.8
22 TP 781 544.69 3.2 2.2 4 3.1 5 2.4 1.8 4 3.5 3.8
23 TP 821 427.50 0.55 1.1 1.8 7 3.8 1.8 2.4 3.1 3.8 2.2
24 TP 769 479.53 0.7 0.8 0.5 0.45 1 0.39 0.4 2.8 1.9 2.2
25 TP 801 525.98 3.2 2.4 6 4.1 4 2.8 2.8 3 2.8 3
26 TP 765 750.85 2.4 1.1 .10 3 4.1 2.8 2 3 4 3.8
27 TP 826 506.59 0.58 0.9 0.6 4 0.8 0.25 0.56 2 1.2 1.8
28 TP 764 318.37 7 6 6 .10 8 .10 9 .10 .10 .10
29 TP 825 335.42 1.2 4.5 4 5.1 5 2.2 3.5 3.1 3.9 3
30 TP 740 399.53 2 0.9 2.1 2 1.2 0.7 0.72 2.6 2.8 3
31 TP 785 445.30 2.7 2.2 3.4 3.8 2.8 3.5 2.8 2.8 3 2.3
32 TP 835 577.67 3 3 3.6 3 2 0.7 2.5 1.2 2.2 3.2
33 TP 812 412.89 3.1 1.5 3.2 3.5 3.1 .10 2.8 2.9 3.8 3.7
doi:10.1371/journal.pone.0013131.t006
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respiration and blockade of complex I function. The observed
decrease in OCR was accompanied by a temporal increase in
superoxide production beginning as early as ten minutes post
treatment and continuing for up to 24h and a transient increase in
the rate of extracellular acidification indicative of glycolysis. It is
likely these early events contribute significantly, if not wholly, to
the TP mechanism of action.
To our knowledge, this is the first paper to evaluate the cellular
response to triphenylphosphonium compounds at the proteomic
level, and thus provides insight on the retrograde mitochondria-
to-proteome response. A mechanism for the late action of TP
analogues can be related to the significant alterations observed in
signal transduction cascades relevant to cancer cell biology after
24 hours treatment. (Fig. 8) In response to TP421, MDA-MB-
435 cells showed a marked down-regulation of key signal
transducers governing cellular responses to growth factors,
cytokines, hormones, and adhesion to extracellular matrix that
ultimately impinged upon the expression of cyclins D1 and E,
retinoblastoma protein phosphorylation and phopshorylation of
the c-jun transcription factor. In addition to the pathways
depicted above, significant decreases in expression or activation
state were noted for proteins involved in or related to the
regulation of cell cycle progression, protein folding and
chaperoning, intracellular calcium signaling, mitogenic signaling,
and cell adhesion. TP treatment also significantly increased the
abundance and activation state of numerous protein serine
phosphatases, activators of NFkB, PKC isoforms and the
members of the STAT family of transcription regulators. These
alterations in protein abundance and function, due to their ability
to modulate cell fate, are also likely contributors to the later phase
mechanisms of TP action.
Although the data reported here does not elucidate the exact
relation between the earlier and later responses and the degree to
which each contributes to the outcome of TP response, it is
possible to predict a generalized mechanism of action based on the
probable interplay of temporal events.
Superoxide produced in the mitochondria in response to
inhibition of oxygen consumption can be converted to hydrogen
peroxide, hydroxyl radical or in the presence of nitric oxide,
peroxynitrite.[27,28,29,30] These ROS derivatives can diffuse or
be transported out of the mitochondria to enter the cytosolic and
nuclear compartments. ROS can react with thiols of cysteine and
methionine residues of proteins, in both the cytosol and nucleus,
causing either intra- or extracellular disulfide linkages. Disulfide
linkages modify protein structure, which can directly impact
function thorough alterations in protein activity, protein/protein
associations and sub-cellular localization. In the nucleus, ROS can
also act to inhibit transcription factors by altering their redox
status while higher concentrations of ROS have been shown to
induce oxidative DNA damage.[31,32]
The cellular response to ROS production is dependent on the
cellular redox buffering potential as well degree and duration of
ROS production. Abrupt, intense ROS over production may
overwhelm cellular antioxidant responses causing irreversible
oxidative damage to cellular proteins, lipids and DNA leading to
oxidative stress and ultimately cell necrosis. Lower levels of ROS
production, on the other hand, produce milder oxidative
imbalances that via redox mediated regulation of signal transduc-
tion result in programmed responses such as cell proliferation,
senescence and apoptosis.[32,33]
Based on this knowledge, it is plausible that TP compounds,
through selective inhibition of tumor cell oxygen consumption and
subsequent superoxide generation in the mitochondria, contribute
to sustained, low levels of ROS production. The sustained levels of
ROS eventually create an imbalance in the cellular redox status
that causes modulation in the function of proteins involved in cell
cycle regulation, growth factor signaling and DNA transcription
resulting in the global protein expression profile observed in the
Kinexus data. Dyfunction in these molecular effectors impinges on
pathways critical to cancer cell survival, proliferation and
interaction with the extracellular environment leading to the
induction of apoptosis.
Full elucidation of the mechanism of TP action is beyond the
scope of this report but, with these analyses, we demonstrate that
TP analogues impact multiple pathways relevant to cancer cell
survival, growth, cell cycle progression, cell adhesion and motility
and apoptosis, many of which have demonstrated sensitivity to
intracellular redox status. Taken together the results of our studies
involving TP compounds suggest a unique mechanism of action
that includes inhibition of oxygen consumption leading to
sustained increases in free radical production which alter redox
sensitive cell signaling pathways to inhibit growth factor mediated
signaling, promote cell cycle arrest and induce apoptosis.
Materials and Methods
Cell culture
MDA-MB-435 breast, MCF7 breast cancer and PC3 prostate
cancer cell lines were purchased from the American Type Cell
Culture (Manassas, VA). HCT116 p53+/+ and HCT116 p53-/-
cells were kindly provided by Dr. Bert Vogelstein (Johns Hopkins
Medical Institutions, Baltimore, MD). Cell lines were maintained
in the appropriate growth media (DMEM for MDA-MB-435,
MCF7 and PC3, RPMI for the HCT116 cell lines) containing
10% heat-inactivated fetal bovine serum and supplemented with
2 mM L-gutamine at 37uC in a humidified atmosphere of 5%
CO2. For subculture and experiments cells were washed with 1x
PBS, detached using 0.025% Trypsin-EDTA (Cellgro, Mediatech,
Mannassas, VA), collected in growth media and centrifuged. All
experiments were performed in growth media using sub-confluent
cells in the exponential growth phase. For use in tissue culture
experiments, compounds were prepared at 10 mM concentration
in sterile dimethylsulfoxide (DMSO) (EMD Chemicals, Gibbs-
town, NJ) and stored at 220uC when not in use.
Cytotoxicity assay
Cytotoxicity was assessed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay as previously de-
scribed.[34] Cells were seeded in 96-well tissue culture treated
dishes and allowed to adhere overnight. Cells were subsequently
treated with a continuous exposure to drugs for 72 hours. An
MTT solution was added to each well to give a final
concentration of 0.3 mg/mL MTT. Cells were incubated with
MTT for 3–4 hours at 37uC. After removal of the supernatant,
DMSO was added and the absorbance was read at 570 nm. All
assays were done in triplicate. The IC50 was then determined for
each drug from a plot of log drug concentration versus percentage
of cell kill.
Colony formation assay
Colony formation assay was performed as previously described
[35] to further assess drug toxicity. To this end, cells were seeded
in 96 well tissue culture dishes at a density of 200 cells per well in
growth media and allowed to adhere overnight. Cells were
subsequently treated with varying concentrations of compound for
24 h. Following treatment, monolayers were washed with 1x PBS
and incubated in growth media for a period of 7–10 days, allowing
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extent of colony formation, cells were fixed and stained in a 2%
solution of crystal violet containing 1% glutaraldehyde. Excess
stain was removed through multiple washes in distilled water and
allowed to air dry. Stained plates were imaged using Quantity One
software running on the VersaDoc imaging platform. (BioRAD).
Quantification by measurement of optical density at 570 nm was
performed after solublization in a 2% solution of sodium dodecyl
sulfate accompanied by 2 h shaking on a platform rocker.
Cell cycle analysis
Cells were seeded in 100 mm tissue culture dishes at a density of
1610
6 cells/plateingrowthmediaand allowedtoadhereovernight.
The following day cells were treated with IC80 concentrations of TP
compounds or DMSO alone as vehicle control for 24–72 h. Upon
completion of treatment, cells were detached with trypsin and both
media and cells were collected by centrifugation. Cells were washed
and resuspended in 1x PBS prior to fixation in ethanol overnight at
220uC. Fixed cells were treated with 10 mg/mL RNase A (Sigma-
Figure 8. Proposed mechanism of action. TP compounds reduce mitochondrial oxygen consumption, and increase superoxide leading to the
formation of ROS species that cause attenuation of signaling pathways involved in cancer cell growth and proliferation. Using the IPA platform,
proteins exhibiting significantly up- or down- regulated expression or phosphorylation (denoted by *) were examined in the context of signaling
pathways involved in cancer cell survival mediated by growth factors, cytokines, cell adhesion and hormones. TP-treatment impinged on key
signaling molecules in the MAPK (mitogen activated protein kinase), JNK (c-jun N-terminal kinase), PI3K/Akt/mTOR (phosphotidylinostiol-3-kinase/
Akt/mammalian target of Rapamycin), and CAMK (calcium-calmodulin kinase) pathways leading to suppression of cyclin D1 expression and c-jun
phosphorylation coupled with an increase in Rb phosphorylation.
doi:10.1371/journal.pone.0013131.g008
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propidium iodide (Sigma-Aldrich, St. Louis, MO). DNA content
was determined by flow cytometry using the BD LSR II (BD
Biosciences, San Jose, CA) equipped with a 488 nM Sapphire
TM
argon-ion laser and PE emission detector.
Xenograft studies
1.5610
6 MDA-MB435 cells were implanted subcutaneously
into the rear flank of 6-week old female nu/nu mice (Charles River
Laboratories, Wilmington, MA). When tumor volumes reached
100 mm
3, mice were separated into one of six treatment groups
consisting of four to eight mice per group. Treatments were
administered by intraperitoneal injection in a 50 mL suspension of
5% DMSO/95% peanut oil (v/v). Group 1 (n=8) received vehicle
control of DMSO/peanut oil. Group 2 (n=4) received 10 mg/kg
body weight paclitaxel every other day for a total of seven doses.
Group 3 (n=8) received 10 mg/kg body weight TP187, five times
weekly. Group 4 (n=8) received 10 mg/kg body weight TP197
every other day. Group 5 (n=8) received 10 mg/kg body weight
TP449 five times weekly. Tumor volumes and weights were
measured three times weekly. Tumors were measured using
calipers. Tumor volume was calculated using the following
equation: V= d
2 6 D/2 , where d=the width or smaller
measure and D= the length or larger measure. Data collected was
plotted and analyzed to determine average tumor volumes and
weights, SEM values, and p-values using Microsoft Excel. Health
checks were performed daily. Mice exhibiting toxicities or
excessive tumor burden (. 2.0 cm
3) were sacrificed using CO2
gas, necropsies were performed and tumor samples and organs
were harvested and fixed in 10% neutral buffered formalin prior to
processing for histological analysis. Upon completion of the
experiment remaining mice were sacrificed and following
necropsy, the organs harvested, fixed and processed for histolog-
ical analysis. The animal studies were approved by the USC
Animal Care and Use Committee under protocol numbers 10766
and 11458. Animal care and manipulation were in agreement with
the USC institutional guidelines, which were in accordance with
the Guidelines for the Care and Use of Laboratory Animals.
Tissue handling
Surgically excised tissues or organs were washed in 1x PBS to
remove blood and bodily fluids prior to fixation in 10% neutral
buffered formalin. Samples were fixed for 24–48 hour after which
time the organs were stored in 1x PBS until ready to process for
analysis. Fixed samples were placed in cassettes and processed for
histological analysis using the Microm STP 120 spin tissue
processor (Richard Allen Scientific, Kalamazoo, MI). At the
completion of the processing, tissues/organs were embedded in
molds containing hot paraffin and allowed to solidify on the
Microm EC 350-2 refrigerated cooling tray. Paraffin blocks were
cooled on ice and 4-micron sections were cut using a Microm HM
310 microtome (Microm International GmBH, Walldorf, Ger-
many). Paraffin embedded sections were floated in a Thermo
Scientific Tissue Flotation bath filled with water heated to 44uC
prior to mounting on pre-cleaned, positively-charged glass slides
(Richard Allen Scientific, Kalamazoo, MI). Slides were placed
upright and allowed sufficient time to air dry.
Hematoxylin and eosin staining
H&E staining was performed using Thermo Scientific Shandon
Varistain Gemini automated stainer (Richard Allen Scientific,
Kalamazoo, MI). The Gemini stainer was programmed as follows.
Slides were deparaffinized in the heater block for 20 minutes. The
program then continued with incubation of slides in 3 changes of
Clear-Rite 3 for three minutes followed by two changes of
FLEX100 for one minute each. The slides were then incubated in
FLEX 95 for one minute before a running water wash. After the
water step, slides were stained with Hematoxylin 7211(Richard
Allen Scientific, Kalamazoo, MI) for two minutes, thirty seconds
followed by a one minute running water wash. Next, the slides were
incubated one minute with Clarifier 2 (Richard Allen Scientific,
Kalamazoo, MI) to remove background hematoxylin staining.
Clarifier 2 treatment was followed with a one-minute running water
washprior to a one-minute incubationwith bluing reagent (Richard
Allen Scientific, Kalamazoo, MI). After the bluing reagent, the
slides were washed one minute in runningwater and then incubated
for thirty seconds in FLEX 95. The slides were then stained with
Eosin Y (Richard Allen Scientific, Kalamazoo, MI ). Eosin Y
staining was followed with three consecutive one minute washes in
100% FLEX and finally three consecutive changes of Clear-rite 3
(Richard Allen Scientific, Kalamazoo, MI). The slides were then
removed from the Gemini stainer and coverslipped using 1–2 drops
of mounting media (Richard Allen Scientific,) and air dried several
hours. Specimens were examined by light microscopy. Slides were
visualized using a Ziess axioscope light microscope equipped with
10 x eyepiece and 5, 20, 40 and 100 x objectives. Light micrographs
were obtained using Moticam 2300 microscope camera (Motic in
North America, Richmond, BC, Canada).
Immunoperoxidase staining of formalin-fixed paraffin-
embedded tissue sections
Tissue sections four microns thick were mounted on pre-cleaned
positively charged glass slides. Tissue sections were deparaffinized
using three changes of xylenes for five minutes each. Sections were
hydrated, first in two washes of 100% ethanol for 10 minutes each,
then two washes in 95% ethanol for 10 minutes each followed by
immersion in double distilled water (ddH2O) for one minute.
Antigen retrieval was performed by boiling slides for ten minutes
in 10 mM sodium citrate pH 6.0. Immunohistochemical staining
was performed using the UltraVision ONE detection system
(Thermo Scientific, Fremont, CA) according to the manufacturer’s
protocol. MDM2 (clone SMP14) was obtained from Biosource,
Invitrogen, (Carlsbad, CA). p53 antibody (clone DO-1) was
obtained from Santa Cruz Antibodies (Santa Cruz, CA) and used
at dilutions of 1:500. Ki67 antibody (clone SP6) was obtained from
Thermo Scientific (Fremont, CA) and was used at a dilution of
1:400. Anti-cleaved Caspase 3 antibody was purchased from Cell
Signaling (Danvers, MA) and was used at a 1:400 dilution. IgG
isotype controls for rabbit and mouse were purchased from Santa
Cruz antibodies and used at dilutions of 1:400 and 1:500 as
negative controls in all staining procedures. Immunolabelled
sections were counterstained for 10 seconds with hematoxylin
7211 (Richard Allen Scientific, Kalamazoo, MI) and rinsed in
ddH2O three to four times to remove excess stain. Tissue sections
were then dehydrated through two ten-second washes in 95% and
100% FLEX alcohol (Richard Allen Scientific, Kalamazoo, MI),
followed by three five-second changes of Clear-rite 3. Excess
clearite was blotted and slides were mounted using clarion
mounting medium (Sigma-Aldrich, St. Louis, MO) and glass
coverslips. Slides were air-dried overnight prior to microscopy.
Q-Score method for quantification of nuclear
immunohistochemical staining
Q-score is a semi-quantitative method of tissue scoring using the
formula Q= P x I, where P is equal to the percentage of positively
staining cells and I is equal to the intensity at which each positve cell
stains. I or intensity, is given a value between 1 and 3, representing
Mitochondria-Targeted Drugs
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in controlversesTP187 treated tumorsections, three tumor sections
from each treatment were examined. For each, at least 10 random
fields were photographed and P and I values were calculated for
each individual field. The average Q-score and the corresponding
SEM were calculated in this way for each treatment.
Statistical analysis
Statistical analysis was performed for tumor volumes and Q-
scoring of immunohistochemical staining in Microsoft Excel using
the Student’s t-test, assuming unequal variances. P-values less than
0.05, obtained by this method were considered to be significant.
Flow cytometric analysis of TP421 uptake
The fluorescent properties of TP421 were exploited to
investigate the cellular uptake of TP compounds. PC3 prostate
cancer cell lines were seeded at a density of 5.0610
5 cells/dish in
33 mm tissue culture-treated dishes and allowed to adhere
overnight in 2 mL growth media. The following day cells were
collected by trypsinization, washed and resuspended in 500 mL1 x
PBS. Three minutes prior to, and immediately following addition
of 10 mM TP421 or DMSO, as vehicle control, fluorescence versus
time was recorded for emission wavelengths between 425–475 nM
in response to excitation with the 355 nM UV solid state laser of
the BD LSR II flow cytometer.
Fluorescence spectroscopy
Fluorescence spectroscopy was performed on TP compounds
and MitoSOX to determine optimal excitation and emission
wavelengths using the Fluorolog 3, steady state spectrofluorimeter
(Horiba Scientific, Edison, NJ). Spectroscopy was performed using
5–10 mM compound dissolved in dimethylsulfoxide (DMSO)
(EMD Chemicals, Gibbstown, NJ) resuspended in 2 mL ddH2O.
Readings were corrected to remove background fluorescence
corresponding to DMSO and ddH2O.
Flow cytometric analysis of ROS formation
MDA-MB-435 cancer cells were treated with 2 mMT P
compounds for various time periods prior to incubation with
5 mM MitoSOX Red Mitochondrial Superoxide Indicator (Invitro-
gen, Carlsbad, CA) at 37uC for 10 minutes. Cells were trypsinized,
washed three times with Hank’s Balanced Salt Solution (HBSS) to
remove residual MitoSOX before resuspending in 750 mL1 xP B S .
Fluorescence intensity correspondingto oxidationof MitoSOX Red
by superoxide radicals was recorded for emission wavelengths
between 562–588 nM in response to excitation with the 488 nM
Sapphire
TM argon-ion laser of the BD LSR II flow cytometer.
Bioenergetics studies
Bioenergetics studies were conducted using an XF 24
Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA).
The assays were performed in a disposable sensor cartridge
containing 24 pairs of fluorescent biosensors coupled to a
fiberoptic waveguide, and a 24 well XF24 cell culture microplate.
To prepare the biosensor cartridge, the biosensors were
hydrated by adding 1 mL of XF24 calibrant solution (Seahorse
Bioscience, Billerica, MA) in each well of the XF24 biosensor
cartridge. The cartridge was then incubated overnight at 37uC
without an external CO2 source. Concurrently, MDA-MB-435
cells were seeded at a density of 120,000 cells per well in a 100 mL
culture medium in each of 20 wells of the XF 24 cell microplate
leaving A1, B4, C3 and D6 control wells blank. The cells were
allowed 4 h to adhere prior to the addition of 150 mL of culture
media to each well. The plate was subsequently incubated
overnight at 37uC in the presence of 5% CO2.
At the onset of bioenergetics measurements, the assay medium
was warmed to 37uC, and the pH was adjusted to 7.4. Culture
media was removed from the XF24 cell microplate, and the wells
were rinsed with 1 mL assay medium. Next, 600 mL of the assay
medium was added to each well, and the XF24 cell microplate was
incubated at 37uC for 1 h without CO2 supplementation.
Dilutions of the stock compounds were prepared in assay media.
A volume of 60 mL reagent was added the injection ports of the
biosensor cartridge, and were maintained at 37uC without CO2
supplementation. Calibration and assay measurements were
performed at 37uC. The data generated reflects measurements
taken over a treatment period of seven hours.
Bioenergetics assay medium
The bioenergetics assay medium was prepared by dissolving
DMEM base (8.3 g/L, Sigma, St. Louis, MO) in 500 mL distilled
water. 1.85 g of sodium chloride (Sigma, St. Louis, MO) was
dissolved separately in 500 mL of distilled water. Solutions of
sodium chloride and DMEM base were then combined and
20 mL of this combined solution was replaced with 10 mL of 100
x GlutaMax-1 (Gibco), and 10 mL of 100 mM sodium pyruvate
(Sigma-Aldrich, St. Louis, MO). The media was then warmed to
37uC. The pH of the media was adjusted to 7.4 using 5 M sodium
hydroxide (Sigma, St. Louis, MO). Finally, the media was
sterilized by filtration and stored at 4uC for future use at which
time the temperature and pH of the media were again adjusted to
37uC and 7.4, respectively on the day of the assay.
Kinexus antibody microarray
MDA-MB-435 cells were treated with 1 mM of TP421 for 24 h.
Upon completion of treatment, cells were washed in ice-cold PBS to
remove residual medium, then lysed in 200 mL of lysis buffer
(20 mM MOPS, pH 7.0, 2 mM EGTA, 5 mM EDTA, 30 mM
sodium fluoride, 60 mM b-glycerophosphate, pH 7.2, 20 mM
sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonylfluoride, 3 mM benzamidine, 5 mM pepstatin
A, 10 mM leupeptin, 1% Triton X-100, 1 mM dithiothreitol) and
collected. The cell lysates were sonicated on ice, four times for 10 s
each pausing for 15 s intervals between pulses, to rupture the cells
and shear DNA. After sonication, the homogenates were cleared by
centrifugation at 90,0006g for 30 min at 4uC. The supernatants
were transferred to a clean microcentrifuge tube and the protein
concentrations were measured using the BCA protein assay. Whole
cell lysates in a final volume of 250 mL were submitted to Kinexus
for a 628-antibody microarray analysis using the Kinex
TM KAM-
1.1 Antibody Microarray (Kinexus Bioinformatics Corp).
Ingenuity Pathway Analysis
Potential intracellular signaling pathways or molecules affected
by TP421 treatment were identified using the Ingenuity Pathway
Analysis (IPA) software to analyze the Kinexus
TM antibody
microarray results. The significantly up-regulated or down-
regulated pan-specific or phopsho-proteins with their Swiss-Prot
accession numbers and the ratio changes were uploaded as an
Excel spreadsheet file to the IPA server. TP421-mediated signaling
pathways were analyzed by core analysis.
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